Filed Pursuant to Rule 424(b)(5)

Registration No. 333-271386

PROSPECTUS SUPPLEMENT

(To Prospectus Supplement dated December 13, 2023

and Base Prospectus dated June 9, 2023)

____________

Genprex, Inc.

____________

Up to $2,172,381

Common Stock

____________

This prospectus supplement (this “Supplement”) amends, modifies, supersedes and supplements certain information contained in, and should be read in conjunction with, our prospectus supplement, dated December 13, 2023 (the “Original Prospectus Supplement”), and the accompanying base prospectus, dated June 9, 2023 (the “Base Prospectus” and, collectively with the Original Prospectus Supplement, the “Prospectus”). This Supplement should be read in conjunction with the Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectus. This Supplement is not complete without, and may only be delivered or utilized in connection with, the Prospectus, and any future amendments or supplements thereto. The information in this Supplement gives effect to the one-for-forty (1-for-40) reverse stock split of our common stock, par value $0.001 per share, effected at 12:01 am Eastern Time on February 2, 2024.

In accordance with the terms of the At The Market Offering Agreement (the “Sales Agreement”), dated December 13, 2023, that we entered into with H.C. Wainwright & Co., LLC (“Wainwright”), we may offer and sell shares of our common stock from time to time through Wainwright, acting as sales agent or principal, having an aggregate offering price of up to $2,172,381. 

On April 1, 2024, the date we filed our Annual Report on Form 10-K for the year ended December 31, 2023, we became subject to the offering limits in General Instruction I.B.6 of Registration Statement on Form S-3.

We are filing this Supplement to amend the Prospectus to update the amount of our common stock we are eligible to sell under General Instruction I.B.6 to Form S-3. As a result of these limitations and the current public float of our common stock calculated as set forth below, and in accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $2,172,381 from time to time through Wainwright. If our public float increases such that we may sell additional amounts of common stock in excess of the aforementioned aggregate offering price as provided for in this Supplement under the Sales Agreement and the registration statement and Prospectus of which this Supplement and the Original Prospectus Supplement are a part, we will file another prospectus supplement prior to making such additional sales in excess of the aforementioned aggregate offering price as provided for in this Supplement.

Our common stock is listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “GNPX”. On May 17, 2024, the last reported sales price of our common stock on Nasdaq was $2.55 per share. As of May 20, 2024, the aggregate market value of our common stock held by non-affiliates, or the public float, pursuant to General Instruction I.B.6 of Form S-3 was $6,517,145, which was calculated based on 2,095,545 shares of our common stock outstanding held by non-affiliates as of May 20, 2024 and at a price of $3.11 per share, the last reported sale price for our common stock on April 3, 2024. As of the date hereof, we have not offered and sold any common stock pursuant to General Instruction I.B.6 of Form S-3 during the prior 12 calendar month period that ends on and includes the date hereof.

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page S-5 of the Original Prospectus Supplement, Page 5 of the Base Prospectus, and the risks discussed under similar headings in documents incorporated by reference into the Prospectus, as they may be amended, updated or modified periodically in our reports filed with the Securities and Exchange Commission.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this Supplement or the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

FORWARD-LOOKING STATEMENTS

You should carefully consider the risk factors set forth in or incorporated by reference into the Prospectus, as well as the other information contained in or incorporated by reference into this Supplement and the Prospectus. This Supplement, the Prospectus and documents incorporated therein by reference contain forward-looking statements regarding events, conditions, and financial trends that may affect our plan of operation, business strategy, operating results, and financial position. You are cautioned that any forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Actual results may differ materially from those included within the forward-looking statements as a result of various factors. Cautionary statements in the “Risk Factors” section of the Original Prospectus Supplement, the Base Prospectus and in documents incorporated by reference into the Prospectus identify important risks and uncertainties affecting our future, which could cause actual results to differ materially from the forward-looking statements made or included in this Supplement and the Prospectus.

H.C. Wainwright & Co.

The date of this prospectus supplement is May 20, 2024.